Microsatellite instability—a useful diagnostic tool to select patients at high risk for hereditary non-polyposis colorectal cancer: a study in different groups of patients with colorectal cancer

BACKGROUND Clinical diagnosis of hereditary non-polyposis colorectal cancer (HNPCC) is based on a typical family history. As molecular genetic testing is predominantly restricted to these families, gene carriers not meeting the clinical criteria may be missed. AIMS To examine the value of microsatel...

Full description

Saved in:
Bibliographic Details
Published inGut Vol. 44; no. 6; pp. 839 - 843
Main Authors Lamberti, C, Kruse, R, Ruelfs, C, Caspari, R, Wang, Y, Jungck, M, Mathiak, M, Malayeri, H R H, Friedl, W, Sauerbruch, T, Propping, P
Format Journal Article
LanguageEnglish
Published London BMJ Publishing Group Ltd and British Society of Gastroenterology 01.06.1999
BMJ
BMJ Publishing Group LTD
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:BACKGROUND Clinical diagnosis of hereditary non-polyposis colorectal cancer (HNPCC) is based on a typical family history. As molecular genetic testing is predominantly restricted to these families, gene carriers not meeting the clinical criteria may be missed. AIMS To examine the value of microsatellite instability (MSI) as a tool to increase the likelihood for uncovering a mismatch repair germline mutation in patients with colorectal cancer and to identify a genotype-phenotype relation in families with verified mutations. METHODS Systematic search for germline mutations (hMSH2 and hMLH1 genes) was performed in 96 patients: 57 fulfilled the Amsterdam criteria (group 1) and 12 the looser HNPCC criteria (group 2). Seventeen patients showed familial clustering of cancers (group 3) and 10 patients under 50 years had sporadic cancer (group 4), the latter of whom all exhibited MSI+ tumours. RESULTS A similar proportion of germline mutations was found in patients who fulfilled the clinical criteria of HNPCC and had MSI+ tumours (groups 1 and 2; 15/39) compared with patients who did not meet these clinical criteria but who had MSI+ tumours (groups 3 and 4; 8/27 patients). Affected relatives of patients with hMLH1 mutations showed a significantly higher frequency of colorectal cancer but a lower frequency of endometrium cancer than those with hMSH2 mutations. CONCLUSIONS MSI in tumour tissue is a useful criterion for selecting patients who should be tested for germline mutations in the mismatch repair genes hMSH2 and hMLH1 irrespective of their family history. Among carriers of hMSH2 mutations the tumour spectrum was broader than among carriers of hMLH1 mutations.
Bibliography:local:gutjnl;44/6/839
ark:/67375/NVC-2WBNV6Q6-8
PMID:10323887
href:gutjnl-44-839.pdf
istex:88C975C64FFEDEC61E8EBB24A7586D01528BA7EE
Dr C Lamberti, Department of Internal Medicine, University of Bonn, Sigmund-Freud-Str. 25, D-53105 Bonn, Germany.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0017-5749
1468-3288
1458-3288
DOI:10.1136/gut.44.6.839